Clario, a software provider for drugmakers, has confidentially filed for an initial public offering (IPO) in the United States, targeting a valuation of more than $10 billion, Bloomberg reports. The company, which was named the top Biotechnology Company of 2024 by The Healthcare Technology Report, helps drugmakers advance treatments through clinical trials. Clario is backed by Nordic Capital and Astorg and has hired JPMorgan, Morgan Stanley, Jefferies, and UBS to assist with the listing.
Clario files confidentially for US IPO, Bloomberg reports https://t.co/RUi89AN5LP https://t.co/gmk0Wmq8KB
pharma tech scoop: Clario has filed confidentially for an IPO that could value it at more than $10 billion, per sources. The co., backed by Nordic Capital and Astorg, has hired JPM, MS, Jefferies and UBS to help with a listing. story w/ @rngould @DNair5 https://t.co/N7AnLhuLL7
Clario files confidentially for US IPO, Bloomberg reports https://t.co/hk7k2ezT70 https://t.co/7C7ir06BvF
Clario, a provider of software to help drugmakers advance treatments through clinical trials, has filed confidentially for an IPO and is targeting a valuation of more than $10 billion, people familiar with the matter said. https://t.co/dCQpTUfuhv
🔵 CLARIO FILES CONFIDENTIALLY FOR US IPO, BLOOMBERG REPORTS Clario, a software provider for drugmakers, has confidentially filed for an initial public offering in the United States and is targeting a valuation of more than $10 billion, Bloomberg News reported on Tuesday. Full… https://t.co/y3QWmwMARr
Clario said to file confidentially for US IPO @business Clario was named the top Biotechnology Company of 2024 by The Healthcare Technology Report which seems pretty cool until one pans down to #4, Gingko Bioworks ($DNA). Biotech investors may wish to leg into the Clario IPO…